pf-06291874
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01499017)
Timeline
Indications
Mechanism of action
- Glucagon receptorANTAGONIST
GCGR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCC[C@H](Oc1cc(C)c(-n2cc(C(F)(F)F)cn2)c(C)c1)c1ccc(C(=O)NCCC(=O)O)cc1- Mol. weight
- 503.52 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544946 ↗
- ChEMBLCHEMBL2381848 ↗
Also known as
- pf-06291874
- pf-06291874
- pf-06291874
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02554877 | Phase 2 | Oct 1, 2015 | Pfizer |
| NCT02175121 | Phase 2 | Aug 1, 2014 | Pfizer |
| NCT01856595 | Phase 1 | May 1, 2013 | Pfizer |
| NCT01794364 | Phase 1 | Jan 1, 2013 | Pfizer |
| NCT01499017 | Phase 1 | Nov 1, 2011 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 5 | 5 | 2 | 2011 |
1 organizations
Page 1 / 1